Last reviewed · How we verify
NCT02300012
A Pilot Study to Investigate Biomarkers in Anterior Cruciate Ligament (ACL) Patients and Healthy Controls
NA trial testing Surgeons knowledge of pre-operative PBIs in Rupture of Anterior Cruciate Ligament in 8 participants. Completed in 20 May 2022.
20 May 2022
Quick facts
| Lead sponsor | United Lincolnshire Hospitals NHS Trust |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 8 |
| Start date | 5 January 2015 |
| Primary completion | 20 May 2022 |
| Estimated completion | 20 May 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Surgeons knowledge of pre-operative PBIs
Conditions studied
- Rupture of Anterior Cruciate Ligament — all drugs for Rupture of Anterior Cruciate Ligament →
Sponsor
United Lincolnshire Hospitals NHS Trust
Who can join
Adults 18 to 45, any sex, with Rupture of Anterior Cruciate Ligament. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Incident rates of ACL rupture are greatest in 16-39 year olds at almost 1 in 1,000. Performance Based Investigations (PBIs) can be used to evaluate and select correct approaches to patient treatment, and biochemical, biomechanical and physiological biomarkers in other conditions are sensitive in distinguishing between disease state severities, type of injuries and responsiveness to treatment. Despite the measurement sensitivity of PBIs, these are not widely used possibly owing to their focus postoperatively where benefits are less worthwhile. This study aims to investigate novel biomarkers as performance based investigations (PBIs) to improve surgical and treatment strategies in anterior cruciate ligament (ACL) patients. The objectives are to identify whether biomarkers, collected before and after operations, can: 1) Assist the surgeon in decision making; 2) Lead to improved prognosis; 3) Be used to predict the outcomes of prognosis, and; 4) Correlate with disease signs/ smoking to help further understand ACL injuries.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02300012
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rupture of Anterior Cruciate Ligament
Currently open trials in the same condition.
- NCT00625885 — Multicenter ACL Revision Study (MARS) · active not recruiting
Other United Lincolnshire Hospitals NHS Trust trials
Trials by the same sponsor.
- NCT07424950 — Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis · Phase 2 · not yet recruiting
- NCT03191370 — Distraction Technique to Reduce Discomfort of Transnasal Fiberoptic Laryngoscopy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02300012 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by United Lincolnshire Hospitals NHS Trust
- Last refreshed: 27 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02300012.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing